ICON, the Nasdaq-listed Irish clinical research group, lost 22% of its value at one stage yesterday after warning that revenue growth would be slower than expected.

Pharmaceutical giant ICON has reported a 47% increase in net revenues to $68.9m (€58.9m) in its Q1 earnings to end August 2003.